Survodutide

Survodutide is a peptide drug and a dual agonist at the glucagon and GLP-1 receptors (a so-called GCGR/GLP-1R co-agonist), placing it in the second generation of incretin-based peptides after pure GLP-1 and dual GIP/GLP-1 agents. This Peptipedia entry gives you the full overview: survodutide is co-developed by Boehringer Ingelheim and Zealand Pharma, has no marketing authorisation yet (Phase 3 is ongoing), is dosed once weekly by subcutaneous injection, and is being investigated in obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH).

What is survodutide?

Survodutide (development code BI 456906) is a glucagon-derived peptide extended with a C18 fatty diacid side chain that binds albumin and enables once-weekly dosing. Unlike semaglutide, survodutide activates not only the GLP-1 receptor but the glucagon receptor in parallel - hence its classification as a second-generation "twincretin".

How does survodutide work?

Survodutide combines two well-characterised metabolic pathways:

• GLP-1 receptor activation: suppresses appetite, slows gastric emptying, lowers postprandial glucose excursions and improves insulin secretion.
• Glucagon receptor activation: stimulates hepatic gluconeogenesis and glycogenolysis, drives lipolysis in fatty liver and increases thermogenic energy expenditure in brown adipose tissue - raising resting energy expenditure.

Preclinical mouse studies showed greater weight reduction than maximally effective semaglutide, with the additional benefit coming mainly from the energy-expenditure component.

Clinical evidence: weight and glycaemia

• Phase 2 obesity (Lancet 2024, le Roux et al.): 386 adults with obesity without type 2 diabetes, dosed over 46 weeks. Mean weight change vs. placebo: -6.2 % (0.6 mg), -12.5 % (2.4 mg), -13.2 % (3.6 mg), -14.9 % (4.8 mg) and -2.8 % on placebo; up to about 19 % weight loss in completers at the highest doses.
• Phase 2 type 2 diabetes (Diabetologia 2024, Blüher et al.): head-to-head vs. semaglutide and placebo over 16 weeks, with greater HbA1c and body-weight reductions on survodutide.
• Phase 3 SYNCHRONIZE programme: SYNCHRONIZE-1 (obesity without T2D) and SYNCHRONIZE-2 (obesity with T2D) are ongoing; baseline characteristics of SYNCHRONIZE-2 were published in 2026. The SYNCHRONIZE-CVOT cardiovascular outcomes trial runs in parallel (design paper, JACC Heart Fail 2024).
• Phase 2 liver (J Hepatol 2024, Lawitz et al.): favourable tolerability and stable pharmacokinetics even in compensated cirrhosis - indication expansion toward MASH is being explored.

Safety and tolerability

The adverse-event profile mirrors the GLP-1 class: predominantly gastrointestinal events (nausea, vomiting, diarrhoea), dose-dependent and concentrated in the titration phase. Severe hypoglycaemia has so far only been elevated when survodutide is combined with sulfonylureas or insulin. Early liver-safety data in cirrhosis are reassuring but still limited.

How does survodutide compare?

In indirect comparisons, survodutide sits between tirzepatide (dual GLP-1/GIP) and retatrutide (triple GLP-1/GIP/glucagon): a larger effect size than pure GLP-1 agonists, somewhat lower theoretical peak efficacy than the triple agonist, but a more mature glucagon-axis safety database. A Bayesian network meta-analysis (Obesity 2025) ranks survodutide among the most effective compounds in its class over 46-68 weeks.

Outlook

First regulatory data from the SYNCHRONIZE-1/-2 Phase 3 readouts are expected from 2026/27, in parallel with the cardiovascular outcomes study. Until then, survodutide is an investigational agent only - any off-trial use, dosing and sourcing falls under the same regulatory limits as other prescription incretin mimetics. If you need to convert trial or physician-prescribed doses, the injection calculator is the right tool.